An Oral Recombinant Vaccine in Dogs against Echinococcus granulosus, the Causative Agent of Human Hydatid Disease: A Pilot Study
2008

Oral Vaccine for Dogs Against Echinococcus granulosus

Sample size: 28 publication 10 minutes Evidence: moderate

Author Information

Author(s): Petavy Anne-Francoise, Hormaeche Carlos, Lahmar Samia, Ouhelli Hammou, Chabalgoity Alejandro, Marchal Thierry, Azzouz Samira, Schreiber Fernanda, Alvite Gabriela, Sarciron Marie-Elisabeth, Maskell Duncan, Esteves Adriana, Bosquet Georges

Primary Institution: Department of Parasitology and Medical Mycology, Lyon University, Lyon, France

Hypothesis

Can an oral recombinant vaccine effectively reduce Echinococcus granulosus infection in dogs?

Conclusion

The oral vaccine significantly decreased the parasite burden in vaccinated dogs by 70% to 80%.

Supporting Evidence

  • The vaccine showed a significant decrease in the number of cestodes in vaccinated dogs compared to controls.
  • Vaccinated dogs had a slower development rate of remaining worms.
  • Results were consistent across trials conducted in Morocco and Tunisia.

Takeaway

The study tested a new vaccine for dogs that helps protect them from a parasite that can make humans sick, and it worked really well!

Methodology

The study involved two trials where dogs were vaccinated with a recombinant vaccine and then challenged with the parasite to assess the vaccine's efficacy.

Limitations

The study had a small sample size and one dog did not respond to the vaccine.

Participant Demographics

Dogs aged between 1 and 6 months from Morocco and Tunisia.

Statistical Information

P-Value

p<0.01

Confidence Interval

(170–1,130)

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pntd.0000125

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication